أقرت منظمة الغذاء والدواء الأمريكية ( FDA ) استخدام دواء ( Vioxx ) لعلاج الهجمات الحادة لمرض الشقيقة، حيث طرحته شركة( Merck& Co )، وهو الأول من نوعه، ويعمل على علاج هجمات الشقيقة الحادة والمزمنة وأعراضها المرافقة . البروفيسور ستيفن سيلبرستين، أستاذ الأمراض العصبية في جامعة جفرسون بفيلادلفيا، قال إنه "من المعروف أن ألم الشقيقة هو من أشد الآلام التي يعاني منها الشخص، وقد ثبت أن حبة واحدة من دواء فيوكس Vioxx يمكن أن تزيل الآلام خلال ساعتين من تناولها لدى معظم المرضى." وبالنسبة الى الجرعة التي ينصح بها الأطباء عند بداية العلاج بهذا الدواء هي 25 ملغ يوميا، على ألا تزيد عن 50 ملغ يوميا. كما يجب على المريض أن يخبر طبيبه في حال كان يشكو من مشاكل سابقة في المعدة، الكلية، أو قصة خناق في الصدر ( ألم صدري ) ، جلطة في القلب ، أو انسداد في احد شرايين القلب، منعا من حدوث أي تأثيرات جانبية . ويذكر ان استخدام الدواء في علاج الشقيقة، جاء بعد اختبارات أجريت على عدد من المرضى، حيث أثبتت أن جرعة واحدة يومية منه، عيار 25 ملغ أو 50 ملغ، أستطاعت أن تخفف الألم الذي كان يشعر به المريض، كما أنها قللت من نسبة حدوث الأعراض المرافقة، بما فيها زيادة التحسس للضوء والضجة ، والشعور بالغثيان . وبالإضافة الى علاج الآم الشقيقة، فيساعد هذا الدواء على تسكين اوجاع الأسنان الحادة والمتوسطة ، وكذلك آلام ما بعد الجراحة العظمية، والعظام المفصلية المزمنة، والتهاب المفاصل الروماتيزمي لدى البالغين. ((( منقول )))

خبر مفرح جداً فالشقيقة لا يعلم بالآمها الا المبتلين بها اعاذنا الله وايكم لكن الذي لم تذكرة.. هل الـ Vioxx علاج نهائي للشقيقة ام انة مجرد مهدئ كما تعودنا؟؟؟؟؟؟ تحياتي

اقتباس الرّسالة الأصليّة كتبت بواسطة الأغبري خبر مفرح جداً فالشقيقة لا يعلم بالآمها الا المبتلين بها اعاذنا الله وايكم لكن الذي لم تذكرة.. هل الـ Vioxx علاج نهائي للشقيقة ام انة مجرد مهدئ كما تعودنا؟؟؟؟؟؟ تحياتي

[align=center]اخي الحبيب امير مشكووووووووووور جدااااااااااااا على تزويدك لنا بأخر الاخبار على فكرة يوجد موقع متخصخص للتعريف بهذا الدواء اذا اردت ان تزوره اضغط هنا مع خالص ودي و احترامي رامي[/align]

تسلم أخي الله يخليك خالص الود

FDA Approves VIOXX® for the Acute Treatment of Migraine in Adults First and only COX-2 Specific Inhibitor Approved to Relieve Pain and Symptoms of Migraine Attacks WHITEHOUSE STATION, N.J., April 1, 2004 -- Starting today, there is a new pain-relieving option to help the millions of migraine sufferers in the United States. VIOXX (rofecoxib), Merck & Co., Inc.’s once-daily arthritis and pain medicine, received approval from the Food and Drug Administration (FDA) for the acute treatment of migraine attacks with or without aura (the warning of an oncoming migraine attack) in adults. VIOXX is the first and only COX-2 specific inhibitor approved to relieve migraine pain and associated migraine symptoms. “The pain from migraines can be excruciating, and can last for several hours or days — people with migraines know how devastating they can be,” said clinical investigator Stephen Silberstein, M.D., professor of Neurology, Jefferson University Hospital School of Medicine and director, Jefferson Headache Center, Philadelphia. “Studies have shown that just one VIOXX relieved migraine headache pain for most patients within two hours, a standard measurement for evaluating the efficacy of migraine treatments.” VIOXX offers a powerful new treatment option for the estimated 28 million Americans who suffer from the effects of migraines. In addition to the new indication to treat migraine pain, VIOXX is approved for the management of acute pain ****d on studies that have shown VIOXX provided effective analgesic relief for moderate to severe dental pain, primary dysmenorrhea and post-orthopedic surgical pain. VIOXX also is approved for the treatment of the chronic conditions of osteoarthritis and rheumatoid arthritis in adults. The new indication for VIOXX for migraine was ****d on two double-blind, placebo-controlled multicenter studies that enrolled approximately 1,600 patients who were treated for a single migraine attack that included headache pain of moderate to severe intensity. Results from the studies demonstrated that a single dose of VIOXX 25 mg or 50 mg provided significant migraine headache pain relief compared to placebo.1 Both doses of VIOXX also reduced the incidence of migraine symptoms including sensitivity to light (photophobia), sound (phonophobia) and nausea. Findings from the two pivotal single-dose studies among patients taking VIOXX 25 mg (n=363), VIOXX 50 mg (n=375) or placebo (n=362) revealed: VIOXX relieved migraine pain at two hours: The percentage of patients reporting headache relief at two hours following initial dose in one study was 54 percent with VIOXX 25 mg and 57 percent with VIOXX 50 mg compared to 34 percent with placebo; and in the second study, the percentage was 60 percent for VIOXX 25 mg, 62 percent for VIOXX 50 mg and 30 percent for placebo (p<0.001 vs. placebo for both studies). VIOXX relieved nausea and sensitivity to light and sound: The cumulative incidence of photophobia, phonophobia and nausea in one study was reduced by 31 percent, 36 percent and 19 percent in patients taking VIOXX 25 mg, VIOXX 50 mg and placebo, respectively; and in the second study, 39 percent of patients taking VIOXX 25 mg and 44 percent taking VIOXX 50 mg experienced a reduction in the incidence of migraine symptoms compared with 23 percent taking placebo (p<0.001 vs. placebo for both studies). VIOXX decreased use of rescue medications: VIOXX significantly reduced the number of patients who took additional medication for their migraine over the 24 hours after taking VIOXX compared to placebo. In studies, VIOXX was effective regardless of gender, race, age or the presence of aura, menses or dysmenorrhea. VIOXX was also effective regardless of whether or not there was a history of prior response to nonsteroidal anti-inflammatory drugs (NSAIDs). Use of VIOXX in conjunction with common migraine preventative medications, such as beta-blockers, calcium channel blockers, tricyclic antidepressants; or oral contraceptives did not affect efficacy. The most common adverse events occurring in patients taking VIOXX compared to placebo in the single-dose studies were dizziness, nausea, somnolence and dyspepsia. In a three-month extension of one migraine study, the most common adverse events among patients taking VIOXX were dizziness, dry mouth, nausea and vomiting. For the acute treatment of migraine attacks, the recommended starting dose for VIOXX is 25 mg once daily. Some patients may receive additional benefit with 50 mg as compared to 25 mg. The maximum recommended daily dose is 50 mg. The safety of treating more than five migraine attacks in any given month has not been established. Chronic daily use of VIOXX for the acute treatment of migraine is not recommended. The safety and effectiveness of VIOXX have not been established for cluster headache, which is present in an older, predominantly male, population. Important information about VIOXX People with allergic reactions, such as asthma, to aspirin or other arthritis medicines should not take VIOXX. In rare cases, serious stomach problems, such as bleeding, can occur without warning. Patients should inform their physicians if they have liver or kidney disease, or a history of angina (chest pain), heart attack or a blocked artery in their heart. VIOXX cannot take the place of aspirin for the prevention of heart attack or stroke. VIOXX should not be used by women in late pregnancy. Commonly reported side effects in clinical trials with VIOXX have included upper-respiratory infections, diarrhea, nausea and high blood pressure. VIOXX is approved in the United States for the relief of the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, management of acute pain in adults and primary dysmenorrhea. The recommended starting dose of VIOXX for the treatment of osteoarthritis is 12.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 25 mg once daily. For rheumatoid arthritis, the recommended dose is 25 mg once daily. The maximum recommended daily dose for osteoarthritis and rheumatoid arthritis is 25 mg once daily. VIOXX 50 mg once daily is the recommended dose for acute pain and primary dysmenorrhea. Use of VIOXX for more than five days in management of pain has not been studied. Chronic use of VIOXX 50 mg is not recommended. Migraine is not just a headache Migraine is a disease that impacts approximately 28 million Americans2, the majority of them women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain which can last anywhere from four to 72 hours. The pain associated with migraine is frequently accompanied by other unpleasant symptoms, including nausea, vomiting and increased sensitivity to light and/or sound. In a recent household survey of more than 23,500 men and women who reported they suffered from migraines3, nine out of 10 (92 percent) described their migraines as moderate or severe, with nearly a half (47 percent) reporting they have experienced migraines for more than 10 years. Among women surveyed, more than half (52 percent) said they experienced migraines anywhere from once a month to more than three per month. The survey also revealed how under-diagnosed migraines are with nearly a quarter (23 percent) noting the last time they discussed migraines with their physician was two years ago or longer and that approximately one-third (34 percent) have never taken a medication for migraine relief. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Forward-looking statement This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect our businesses, particularly those mentioned in the cautionary statements in Item 1 of our Form 10-K for the year ended Dec. 31, 2003, and in our periodic reports on Form 10-Q and Form 8-K (if any) which we incorporate by reference.

[align=center]WOW Great dear dr. Ahmed & Thank you very much 4 all these information Love Rami[/align]